Pacira plummets on Exparel complete response

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) shed $22.47 (20%) to $92.30 on Monday after it received a complete response letter from FDA for an sNDA for Exparel bupivacaine as a nerve block to provide postsurgical analgesia. The company plans to meet with FDA to discuss the CRL, but declined to disclose a timeline or the nature of FDA's concerns. ...